BioCardia, Inc. (BCDA)
| Market Cap | 12.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.23M |
| Shares Out | 10.94M |
| EPS (ttm) | -1.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,112 |
| Open | 1.150 |
| Previous Close | 1.160 |
| Day's Range | 1.135 - 1.160 |
| 52-Week Range | 1.000 - 3.200 |
| Beta | 0.55 |
| Analysts | Strong Buy |
| Price Target | 25.00 (+2,055.17%) |
| Earnings Date | May 13, 2026 |
About BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic he... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for BCDA stock is "Strong Buy" and the 12-month stock price target is $25.0.
News
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disea...
BioCardia Earnings Call Transcript: Q4 2025
Clinical and financial progress continues, with phase III CardiAMP HF data showing significant benefits in key subgroups and regulatory submissions imminent in the US and Japan. Expenses rose modestly, cash burn remains steady, and multiple near-term catalysts are expected.
BioCardia Reports 2025 Business Highlights and Financial Results
SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas...
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ...
BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t...
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ...
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress
SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease...
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality
SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease...
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t...
BioCardia Earnings Call Transcript: Q3 2025
Regulatory progress continues for cell therapy and delivery platforms, with positive clinical data and advancing trials in heart failure and ischemia. Financials show stable expenses, improved cash position, and a runway into Q2 2026.
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t...
BioCardia Regains Compliance with Nasdaq Listing Requirements
SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, a...
BioCardia Announces Pricing of Up To $12 Million Public Offering
$6 million upfront with up to an additional $6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants $6 million upfront with up to an additional $6 million of ...
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up
SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ...
BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025
SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases...
BioCardia Earnings Call Transcript: Q2 2025
CardiAMP Heart Failure trial showed positive subgroup results, with regulatory submissions in Japan and the US progressing and key meetings expected in Q4 2025. R&D expenses rose, cash runway extends into October, and a financing event is planned for September.
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t...
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t...
BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter
SUNNYVALE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dise...
BioCardia Transcript: A.G.P. Virtual Annual Healthcare Company Showcase
A late-stage cell therapy developer presented positive phase III data for ischemic heart failure, with reduced mortality and improved quality of life, and is advancing regulatory submissions in the U.S. and Japan. Pipeline programs target additional cardiac and pulmonary indications, with active partnership discussions ongoing.
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...
BioCardia Earnings Call Transcript: Q1 2025
Q1 2025 saw increased R&D and total expenses, with a net loss of $2.7M and cash of $949K before a modest financing. CardiAMP and CardiALLO trials advanced, MorphDNA received FDA approval, and business development discussions are active across all platforms.
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results
SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study
CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress